Press releasePRNewswire
Scinai Immunotherapeutics
SCNI · NASDAQ
$0.6813−$0.0687 (−9.16%)TodayMarket closed ·
Prev close $0.75
Latest news
- Press releasePRNewswire
Scinai Immunotherapeutics Announces Closing of $4.0 Million Financing Through a Private Placement and Warrant Inducement
- Press releasePRNewswire
Scinai Immunotherapeutics Announces $4.0 Million Financing Through a Private Placement and Warrant Inducement
- NewsVandana Singh
Why Is Scinai Immunotherapeutics Stock Gaining Tuesday?
- Press releasePRNewswire
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
- Press releasePRNewswire
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- NewsAvi Kapoor
Nasdaq Down Over 200 Points; Cellectis Shares Plunge
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releasePRNewswire
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releasePRNewswire
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
- Press releasePRNewswire
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
- Press releasePRNewswire
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
- Press releasePRNewswire
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
- NewsHenry Khederian
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today
- NewsAvi Kapoor
Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results
- Press releasePRNewswire
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
- Press releasePRNewswire
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
- Press releasePRNewswire
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
- Press releasePRNewswire
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
- Press releasePRNewswire
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
- Press releasePRNewswire
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
- Press releasePRNewswire
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
- Press releasePRNewswire
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
- Press releasePRNewswire
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
- Press releasePRNewswire
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
- Press releasePRNewswire
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
- Press releasePRNewswire
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releasePRNewswire
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
- Press releasePRNewswire
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
- Press releasePRNewswire
Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.